Dopamine Gene Profiling to Predict Impulse Control and Effects of Dopamine Agonist Ropinirole

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Dopamine agonists can impair inhibitory control and lead to impulse control disorders in Parkinson disease (PD) patients.
• The underlying mechanisms linking dopamine agonists, impulse control, and genetic factors remain unclear.

Purpose of the Study:

• To investigate the relationship between dopamine gene polymorphisms and the effects of the dopamine agonist ropinirole on impulse control.
• To examine how ropinirole influences response inhibition and decision-making impulsivity in healthy adults based on their genetic risk score.

Main Methods:

• A double-blind, placebo-controlled study involving healthy adults administered single doses of ropinirole (0.5 and 1.0 mg).
• Impulse control was assessed using the stop signal reaction time (RT) task and the Balloon Analogue Risk Task (BART).
• A dopamine genetic risk score was calculated based on polymorphisms in five key genes: COMT, DAT, DRD1, DRD2, and DRD3.

Main Results:

• Individuals with a higher genetic risk score exhibited better impulse control at baseline (placebo condition).
• Ropinirole modulated impulse control in a dose- and genetic risk score-dependent manner.
• Lower genetic risk groups showed improved response inhibition and reduced decision-making impulsivity with ropinirole, while higher genetic risk groups showed impaired response inhibition and increased decision-making impulsivity.

Conclusions:

• Genetic variations in dopamine pathways influence individual responses to dopamine agonists.
• Genotyping may serve as a predictive tool for determining an individual's susceptibility to impulse control changes when treated with dopamine agonists.
• These findings have implications for personalized medicine in managing Parkinson disease and related treatments.